menu search

Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...

October 22, 2023, 6:59 pm

Dupixent® (dupilumab) sbla for treatment of eosinophilic esophagitis (eoe) in children aged 1 to 11 accepted for fda priority review

If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 infla...

September 26, 2023, 5:29 am

Dupixent® (dupilumab) late-breaking phase 3 copd results presented at ats and simultaneously published in the new england journal of medicine

Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbatio...

May 21, 2023, 6:18 pm

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (csu) in adults and adolescents aged 12 years and older accepted for fda review

More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, March 07, 2023 (GLOB...

March 7, 2023, 6:00 am

Dupixent® (dupilumab) approved by european commission as the first and only targeted medicine indicated for eosinophilic esophagitis

Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remiss...

January 30, 2023, 6:00 am

Dupixent® (dupilumab) recommended for expanded eu approval by the chmp to treat children as young as six months old with severe atopic dermatitis

If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in chil...

January 27, 2023, 5:59 am

Fda accepts regeneron, sanofi's filing for review in skin disease

The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for review submitted by Regeneron Pharmac...

May 31, 2022, 12:04 pm

Sanofi-regeneron's dupixent falls short in chronic spontaneous urticaria trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (...

February 18, 2022, 7:11 am

Sanofi-regeneron's dupixent falls short in chronic spontaneous urticaria trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (...

February 18, 2022, 7:11 am

Sanofi-regeneron's dupixent falls short in chronic spontaneous urticaria trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (...

February 18, 2022, 7:11 am

Chmp backs sanofi-regeneron's dupixent for asthma patients aged 6 - 11 years with type 2 inflammation

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use ...

January 31, 2022, 6:44 am

Chmp backs sanofi-regeneron's dupixent for asthma patients aged 6 - 11 years with type 2 inflammation

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use ...

January 31, 2022, 6:44 am

Chmp backs sanofi-regeneron's dupixent for asthma patients aged 6 - 11 years with type 2 inflammation

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use ...

January 31, 2022, 6:44 am


Search within

Pages Search Results: